4-(1H-indol-5-yl)isoquinoline | 1610790-49-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 4-(1H-indol-5-yl)isoquinoline
• CAS: 1610790-49-2
• 化学式: C₁₇H₁₂N₂
• 分子量: 244.296
• InChiKey: DOJQSUPPHUVBRQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.38
• 重原子数：
  19.0
• 可旋转键数：
  1.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.68
• 氢给体数：
  1.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  4-(1H-indol-5-yl)isoquinoline 在 lithium hydroxide monohydrate 、 水 、 sodium hydride 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 36.5h， 生成
  参考文献：
  名称：

  The discovery of indole full agonists of the neurotensin receptor 1 (NTSR1)

  摘要：

  Neurotensin (NT) is an endogenous tridecapeptide found in the central nervous system (CNS) and in peripheral tissues. Neurotensin exerts a wide range of physiological effects and it has been found to play a critical role in a number of human diseases, such as schizophrenia, Parkinson's disease and drug addiction. The discovery of small-molecule non-peptide neurotensin receptor (NTSR) modulators would represent an important breakthrough as such compounds could be used as pharmacological tools, to further decipher the cellular functions of neurotensin, and potentially as therapeutic agents to treat human disease. Herein, we report the identification of non-peptide low-micromolar neurotensin receptor 1 (NTSR1) full agonists, discovered through structural optimization of the known NTSR1 partial agonist 1. In vitro cellular screenings, based on an intracellular Ca(2+) mobilization assay, revealed our best hit molecule 8 (SR-12062) to have an EC50 of 2 μM at NTSR1 with full agonist behaviour (Emax=100%), showing a higher efficacy and ∼90-fold potency improvement compared to parent compound 1 (EC50=178 μM; Emax=17%).

  DOI：

  10.1016/j.bmcl.2014.06.033
• 作为产物：
  描述：

  5-溴吲哚 、 4-异喹啉硼酸 在 palladium diacetate 、 sodium carbonate 、 三苯基膦 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 生成 4-(1H-indol-5-yl)isoquinoline
  参考文献：
  名称：

  设计和合成4-杂芳基1,2,3,4-四氢异喹啉作为三重再摄取抑制剂。

  摘要：

  发现了一系列5-羟色胺转运蛋白（SERT），去甲肾上腺素转运蛋白（NET）和多巴胺转运蛋白（DAT）的4-双环杂芳基1,2,3,4-四氢异喹啉抑制剂。将讨论这些三重再摄取抑制剂（TRIs）的合成和构效关系（SAR）。化合物10i（AMR-2）是一种非常有效的SERT，NET和DAT抑制剂，在大鼠强迫游泳和小鼠尾巴悬液模型中分别以0.3和1 mg / kg（po）的最小有效剂量显示了功效。在这些测定中的有效剂量下，10i在大鼠和小鼠脑中的三个转运蛋白上均表现出明显的占用水平。对10i代谢的研究表明形成了重要的活性代谢产物化合物13。

  DOI：

  10.1021/ml500053b

文献信息

• Novel Pyridyl- or Isoquinolinyl-Substituted Indolines and Indoles as Potent and Selective Aldosterone Synthase Inhibitors
  作者：Lina Yin、Qingzhong Hu、Juliette Emmerich、Michael Man-Chu Lo、Edward Metzger、Amjad Ali、Rolf W. Hartmann

  DOI：10.1021/jm500140c

  日期：2014.6.26

  Pathologically, high levels of aldosterone are associated with severe cardiovascular diseases such as congestive heart failure, hypertension, and myocardial fibrosis. The inhibition of aldosterone synthase (CYP11B2) to reduce aldosterone levels has been proposed as a promising treatment for diseases related to CYP11B2 because it is the crucial enzyme in the biosynthesis of aldosterone. A series of novel pyridyl- or isoquinolinyl-substituted indolines and indoles was designed via a ligand-based approach. The synthesized compounds were tested and found to be strong CYP11B2 inhibitors. The most potent ones showed IC50 values of less than 3 nM, being similarly potent as fadrozole and LCI699. Among them, compounds 14 and 23 showed good selectivity over the highly homologous CYP11B1, with selectivity factors (SF = IC50 CYP11B1/IC50 CYP11B2) around 170; thus, they are superior to fadrozole and LCI699 (SFs < 15). These potent CYP11B2 inhibitors exhibited no inhibition (IC50 > 50 μM) of a panel of hepatic CYP enzymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 and the crucial steroidogenic enzymes, CYP17 and CYP19. Because of these advantageous profiles, compounds 14 and 23 are considered to be candidates for further in vivo evaluation.